400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Cell Cycle / PAK / IPA-3
CAS No.: 42521-82-4
Synonyms: IPA-3
IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).
生物活性
实验方案
技术信息
CAS号 | 42521-82-4 | 储存条件 |
|
|||||||
分子式 | C20H14O2S2 | 运输 | 蓝冰 | |||||||
分子量 | 350.45 | 别名 | IPA-3 | |||||||
溶解度 |
|
动物实验配方 |
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
human 786-0 cell | - | Growth inhibition assay | - | Inhibition of human 786-0 cell growth in a cell viability assay, IC50=3.31805 μM | SANGER |
human 8305C cell | - | Growth inhibition assay | - | Inhibition of human 8305C cell growth in a cell viability assay, IC50=4.16758 μM | SANGER |
human A2780 cell | - | Growth inhibition assay | - | Inhibition of human A2780 cell growth in a cell viability assay, IC50=28.371 μM | SANGER |
human BFTC-905 cell | - | Growth inhibition assay | - | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=5.14768 μM | SANGER |
human BL-41 cell | - | Growth inhibition assay | - | Inhibition of human BL-41 cell growth in a cell viability assay, IC50=3.09844 μM | SANGER |
human BL-70 cell | - | Growth inhibition assay | - | Inhibition of human BL-70 cell growth in a cell viability assay, IC50=2.03796 μM | SANGER |
human CA46 cell | - | Growth inhibition assay | - | Inhibition of human CA46 cell growth in a cell viability assay, IC50=3.6618 μM | SANGER |
human CAL-12T cell | - | Growth inhibition assay | - | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50=5.6414 μM | SANGER |
human CAL-51 cell | - | Growth inhibition assay | - | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50=3.54519 μM | SANGER |
human CCRF-CEM cell | - | Growth inhibition assay | - | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50=5.97667 μM | SANGER |
human CHP-126 cell | - | Growth inhibition assay | - | Inhibition of human CHP-126 cell growth in a cell viability assay, IC50=6.74268 μM | SANGER |
human CMK cell | - | Growth inhibition assay | - | Inhibition of human CMK cell growth in a cell viability assay, IC50=3.14599 μM | SANGER |
human Daoy cell | - | Growth inhibition assay | - | Inhibition of human Daoy cell growth in a cell viability assay, IC50=3.24662 μM | SANGER |
human Daudi cell | - | Growth inhibition assay | - | Inhibition of human Daudi cell growth in a cell viability assay, IC50=5.68477 μM | SANGER |
human DU-145 cell | - | Growth inhibition assay | - | Inhibition of human DU-145 cell growth in a cell viability assay, IC50=8.21464 μM | SANGER |
human EB2 cell | - | Growth inhibition assay | - | Inhibition of human EB2 cell growth in a cell viability assay, IC50=4.49142 μM | SANGER |
human EW-13 cell | - | Growth inhibition assay | - | Inhibition of human EW-13 cell growth in a cell viability assay, IC50=4.20148 μM | SANGER |
human GB-1 cell | - | Growth inhibition assay | - | Inhibition of human GB-1 cell growth in a cell viability assay, IC50=2.63494 μM | SANGER |
human HC-1 cell | - | Growth inhibition assay | - | Inhibition of human HC-1 cell growth in a cell viability assay, IC50=8.06805 μM | SANGER |
human HEL cell | - | Growth inhibition assay | - | Inhibition of human HEL cell growth in a cell viability assay, IC50=3.72768 μM | SANGER |
human HL-60 cell | - | Growth inhibition assay | - | Inhibition of human HL-60 cell growth in a cell viability assay, IC50=8.84605 μM | SANGER |
human HLE cell | - | Growth inhibition assay | - | Inhibition of human HLE cell growth in a cell viability assay, IC50=4.52149 μM | SANGER |
human HOS cell | - | Growth inhibition assay | - | Inhibition of human HOS cell growth in a cell viability assay | SANGER |
human HT-1080 cell | - | Growth inhibition assay | - | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50=18.6283 μM | SANGER |
human HT-1197 cell | - | Growth inhibition assay | - | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50=10.3073 μM | SANGER |
human J82 cell | - | Growth inhibition assay | - | Inhibition of human J82 cell growth in a cell viability assay, IC50=7.04965 μM | SANGER |
human KE-37 cell growth | - | Growth inhibition assay | - | Inhibition of human KE-37 cell growth in a cell viability assay, IC50=3.50231 μM | SANGER |
human KS-1 cell | - | Growth inhibition assay | - | Inhibition of human KS-1 cell growth in a cell viability assay, IC50=6.88549 μM | SANGER |
human KU812 cell | - | Growth inhibition assay | - | Inhibition of human KU812 cell growth in a cell viability assay, IC50=2.7595 μM | SANGER |
human MC-CAR cell | - | Growth inhibition assay | - | Inhibition of human MC-CAR cell growth in a cell viability assay, IC50=5.70644 μM | SANGER |
human MCF7 cell | - | Growth inhibition assay | - | Inhibition of human MCF7 cell growth in a cell viability assay, IC50=2.1807 μM | SANGER |
human MHH-PREB-1 cell | - | Growth inhibition assay | - | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50=3.46687 μM | SANGER |
human MV-4-11 cell | - | Growth inhibition assay | - | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=9.1649 μM | SANGER |
human NALM-6 cell | - | Growth inhibition assay | - | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=0.97694 μM | SANGER |
human NB13 cell | - | Growth inhibition assay | - | Inhibition of human NB13 cell growth in a cell viability assay, IC50=4.2256 μM | SANGER |
human NB6 cell | - | Growth inhibition assay | - | Inhibition of human NB6 cell growth in a cell viability assay, IC50=3.83751 μM | SANGER |
human NB69 cell | - | Growth inhibition assay | - | Inhibition of human NB69 cell growth in a cell viability assay, IC50=6.76352 μM | SANGER |
human NCI-H2009 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50=5.04354 μM | SANGER |
human NH-12 cell | - | Growth inhibition assay | - | Inhibition of human NH-12 cell growth in a cell viability assay, IC50=5.1176 μM | SANGER |
human NOS-1 cell | - | Growth inhibition assay | - | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=11.7152 μM | SANGER |
human PF-382 | - | Growth inhibition assay | - | Inhibition of human PF-382 cell growth in a cell viability assay, IC50=5.35226 μM | SANGER |
human QIMR-WIL cell | - | Growth inhibition assay | - | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=2.90891 μM | SANGER |
human REH cell | - | Growth inhibition assay | - | Inhibition of human REH cell growth in a cell viability assay, IC50=3.36655 μM | SANGER |
human RKO cell | - | Growth inhibition assay | - | Inhibition of human RKO cell growth in a cell viability assay, IC50=5.28471 μM | SANGER |
human RPMI-8402 cell | - | Growth inhibition assay | - | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50=5.76876 μM | SANGER |
human SIG-M5 cell | - | Growth inhibition assay | - | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50=2.10219 μM | SANGER |
human SK-LU-1 cell | - | Growth inhibition assay | - | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=18.8731 μM | SANGER |
human SK-N-DZ cell | - | Growth inhibition assay | - | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50=9.20423 μM | SANGER |
human SR cell | - | Growth inhibition assay | - | Inhibition of human SR cell growth in a cell viability assay, IC50=5.37256 μM | SANGER |
human ST486 cell | - | Growth inhibition assay | - | Inhibition of human ST486 cell growth in a cell viability assay, IC50=4.8654 μM | SANGER |
human SW1710 cell | - | Growth inhibition assay | - | Inhibition of human SW1710 cell growth in a cell viability assay, IC50=1.17833 μM | SANGER |
human SW48 cell | - | Growth inhibition assay | - | Inhibition of human SW48 cell growth in a cell viability assay, IC50=21.8897 μM | SANGER |
human SW872 cell | - | Growth inhibition assay | - | Inhibition of human SW872 cell growth in a cell viability assay, IC50=7.83558 μM | SANGER |
human U-698-M cell | - | Growth inhibition assay | - | Inhibition of human U-698-M cell growth in a cell viability assay, IC50=3.23856 μM | SANGER |
human WSU-NHL cell | - | Growth inhibition assay | - | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50=5.52067 μM | SANGER |
human YT cell | - | Growth inhibition assay | - | Inhibition of human YT cell growth in a cell viability assay, IC50=1.39036 μM | SANGER |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网